Physician profile
Bithika Ray
NPI 1871725804
$1,055.98
in general payments reported to CMS, 2019-2025
44 companies · $192 in 2025
The $192 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $145 · 2021: $23.24 · 2022: $58.49 · 2023: $221 · 2024: $166 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $578.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $97.21 | 2019-2024 | Airsupra |
| Kowa Pharmaceuticals America, INC. | $51.73 | 2019-2022 | |
| Medtronic, INC. | $42.46 | 2023-2025 | Inceptiv, Intellis Adaptivestim |
| Opko Pharmaceuticals, LLC | $39.48 | 2019-2020 | |
| Horizon Therapeutics Plc | $38.55 | 2022-2023 | Krystexxa |
| Merck Sharp & Dohme LLC | $36.51 | 2021-2023 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $36.06 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $30.75 | 2020-2023 | |
| Amgen INC. | $29.55 | 2024 | Tavneos, Krystexxa |
| Lilly USA, LLC | $29.19 | 2023-2024 | Jardiance |
| Shire North American Group INC | $28.79 | 2019 | |
| Calliditas Therapeutics US INC. | $28.78 | 2022-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $28.49 | 2023-2024 | Lupkynis |
| Ardelyx, INC. | $28.44 | 2024 | Ibsrela |
| Genzyme Corporation | $28.13 | 2019-2023 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bithika Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.